deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT04327024

Study of Verinurad in Heart Failure With Preserved Ejection Fraction (AMETHYST)

A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad Combined With Allopurinol in Heart Failure With Preserved Ejection Fraction

Sponsor: AstraZeneca

Conditions Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions Allopurinol Placebo for allopurinol Placebo for verinurad Verinurad
Updated 19 times since 2020 Last updated: Jun 12, 2023 Started: May 19, 2020 Primary completion: Apr 29, 2022 Completion: Apr 29, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Heart Failure With Preserved Ejection Fraction (HFpEF), this trial is completed. The trial is conducted by AstraZeneca and has accumulated 19 data snapshots since 2020. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Jul 2023 · 12 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jul 2022 — Jul 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 14 earlier versions

  1. Mar 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  5. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  6. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  7. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  8. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  9. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  10. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  11. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  12. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  13. Jul 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  14. Apr 2020 — Jul 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aramil, Russia , Bad Oeynhausen, Germany , Bedford Park, Australia , Berlin, Germany , Brezno, Slovakia , Bydgoszcz, Poland , CABA, Argentina , Cheongju-si, South Korea , Chermside, Australia , Chojnice, Poland and 34 more locations